comparemela.com

Latest Breaking News On - Global blood therapeutics - Page 16 : comparemela.com

Pfizer (PFE) Q2 2023 Earnings Call Transcript

Pfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood Disorders - Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals Inc received notice from Pfizer Inc (NYSE: PFE), as successor to Global Blood Therapeutics Inc, exercising its right to terminate the License and Collaboration Agreement dated December 17, 2019, related to the discovery, development, a

Pfizer to end license deal with Syros for blood disorder therapies

(Reuters) - Syros Pharmaceuticals said on Friday Pfizer will terminate a license deal between the companies related to the development of novel therap.

Pfizer to end license deal with Syros for blood disorder therapies

Shares of Syros were down 5.7% in trading after the bell. The termination will end the company's more than three-year long collaboration with sickle cell disease drugmaker Global Blood Therapeutics (GBT) that Pfizer bought in a $5.4 billion deal last August.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.